RBC Capital Markets has initiated Revolution Medicines (RVMD) at outperform, saying that its platform of “RAS(ON)” inhibitors to treat various cancers has demonstrated strong efficacy thus far.
The firm has a $77 price target (~31% upside based on Oct. 31 close).
